Among the reported chemical compounds targeting Hsp90, ATP competitive inhibitors form a dominant group, and quite a few compounds from this group are undergoing clinical trials for the treatment of cancer (Nabi et al., 2018, Sidera and Patsavoudi, 2014, Tatokoro et al., 2015). The gene discussed is HSP90AA1; the disease is cancer.